Israeli biotech Kamada received patent approval for its unique protein proprietary technologies used to produce the company’s intravenous AAT drug. GLASSIA treats chronic emphysema due to congenital deficiency of AAT (Alpha-1 Antitrypsin), an under-diagnosed hereditary condition, which causes irreversible damage to lung tissue, severe lung disease, and even death.
http://www.globes.co.il/serveen/globes/docview.asp?did=1000714334&fid=1725